A phase 1/2 multicenter investigator-initiated trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David R Wise, Russell Kent Pachynski, Samuel R. Denmeade, Rahul Raj Aggarwal, Victor Ricardo Adorno Febles, Arjun Vasant Balar, Minas P. Economides, Cynthia A. Sirard, Andrea Troxel, Sarah Griglun, Dayna Leis, Nina Yang, Viktoriya Aranchiy, Sabrina Machado, Erika Waalkes, Gabrielle Gargano, Fang-Ming Deng, Ezeddin Fadel, Luis Chiriboga, Jonathan Melamed
Institutions: NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Washington University in St. Louis, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, VA NY Harbor Healthcare System, NYU Langone Health, New York University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286294432